Critical Care

Oxylog® 1000 Simply ventilate

The Oxylog® has been the natural choice of emergency care ventilator for more than 25 years. The Oxylog® 1000 is the most compact ventilator in the Oxylog® range.

This device combines the renowned Dräger technology of the Oxylog with the higher demands which are placed on n emergency ventilator today. With its simple and user-friendly operation, the Oxylog 1000 sets standards. he Oxylog 1000 is lightweight and sturdy, making it ideal for mobile use. It offers you all that you need for prehospital emergency ventilation, as well as in-hospital emergency esuscitation.
The Oxylog 1000 also stands for great reliability, thanks to its fundamentaldesign, making it ready to meet rough conditions during your mission. All that the Oxylog 1000 needs to venti- ate your patients is oxygen, giving you the freedom to work wherever you need to.

Easier for you, safer for your patient

– All we need is oxygen – and so does he Oxylog 1000. It functions on the basis of a purely pneumatic system, releasing you from being dependent on additional power-supply or batteries.

– Safety first: Integrated audible and visual alarms alert you to disconnection, stenosis and low supply pressure.
– You care about the well-being of your patient. Delicate lung tissue may be damaged at high pressure levels. The Oxylog 1000 allows limitation of airway pressure through its Pmax. Once the pressure limit is reached, pressure-limited ventilationw with variable volume continues during inspiration.

– In emergency situations, every second counts. Quick handling is required. Familiar control elements laid out in a clear and logical design support optimal and easy operation. The Oxylog‘s user interface may be adjusted according to local customs and definitions.
– An integrated CPR mode allows ventilation, even during resuscitation efforts.

– The extensive DrägerService® network- provides support to you world-wide.

Read More

Gentle for the newborn, efficient for you.

error and time consumption. Until now. D-7346-2009 While neonatal jaundice – or hyperbilirubinemia – occurs in almost all babies, it is a cause of concern for care-givers and anxiety for families. If not treated in time, neonatal jaundice can lead to permanent brain damage1 Screening for jaundice by visual assessment can lead to an overestimation of risk, which means unnecessarylab tests. This blood draw (total serum bilirubin testing (TsB)) requires a heel prick, which is painful for the baby and costly for the hospital. Visual assessment can also lead to an underestimation of risk, which could result in a failure to obtain necessary lab tests. That’s why transcutaneous bilirubin testing (TcB) has grown rapidly in the past few years as a standard practice in hospitals to identify at-risk infants. But even TcB has presented challenges in terms of human.

NEXT-GENERATION JAUNDICE SCREENING FROM DRÄGER

Building on more than 30 years of proven technology 2 he Dräger Jaundice Meter JM-105 is a non-invasive transcutaneous bilirubinometer that measures the yellow- ess of subcutaneous tissue in newborn infants as young as 24 weeks gestational age3 a transfusion or phototherapy. It provides a visual digital measurement that correlates with serum bilirubin results. Effective on heterogeneous populations, the JM-105 can be used in both hospitals and outpatient settings. The JM-105 improves the process of jaundice screening in several ways. The risk of infection is reduced since screening with the JM-105 is non-invasive and drawing blood is not necessary. The device also reduces risk of human
error because it can scan nurse and baby ID information with an optional bar code scanner and can automatically measure, save and transfer data. Not only does this eliminate manual transcription – which can be error prone and time consuming – but it also results in quicker access to information for decision making. , ho have not undergone Readmission Rate for Hyperbilirubinemia. Clinical Chemistry 2005;51 D-94479-2013 Screening with the JM-105 is cost effective because it reduces the frequency of lab tests. And because the device has a reusable probe, expensive disposables are not needed.
Because bilirubin levels peak two to four days after birth – when most babies have gone home – jaundiced babies have to be readmitted for treatment. Since the JM-105 can detect this risk before babies leave the hospital, jaundice can be treated immediately, which can reduce readmissions and lengths of stay 4 .

Read More